On June 8, the reporter learned that its innovative drug in the cardiovascular field, Dolivit, Clopidogrel and Aspirin Tablets (hereinafter referred to as “Doliwei”) was recently opened in Beijing by Huo Yong, director of the Department of Cardiovascular Medicine of Peking University First Hospital. The issuance of the first prescription marks the official arrival of a new treatment option for patients with cardiovascular disease in my country.
On May 22, Sanofi China announced that its innovative drug in the cardiovascular field, Dorivit, Clopidogrel, and Aspirin Tablets was officially launched in China for the prevention of acute coronary syndrome (ACS) in adult patients. Atherothrombotic events.
ACS is a group of clinical syndromes caused by acute myocardial ischemia, mainly due to rupture or erosion of unstable coronary plaques leading to complete or incomplete occlusive thrombus formation. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA), the former two being collectively referred to as acute myocardial infarction (AMI). Among them, the average hospitalization cost of STEMI patients was 40,500 yuan, and the in-hospital mortality rate also climbed from 3.29% in 2019 to 3.48%, bringing a heavy burden to China’s cardiovascular disease.
Huo Yong told reporters that antiplatelet therapy is very important for all atherosclerosis to prevent thrombosis events, or to treat thrombosis events.
“Atherosclerotic disease accounts for more than half of all human deaths from diseases. The pathogenesis of atherosclerotic disease should be said that ‘there is no event without thrombosis’.” Huo Yongsuo, patient There is atherosclerotic disease, there are vascular lesions, there are plaques, there are stenoses, and even if there are symptoms, it will not be fatal. But all deaths of patients are caused by thrombosis, almost without exception, which is a definite conclusion after a century of knowledge.
Huo Yong said that in clinical treatment, dual antiplatelet therapy (DAPT) based on aspirin combined with clopidogrel is the antithrombotic basis for ACS patients, but there are still treatments with low compliance. status quo. According to the CPACS2 study, of the 15,141 adult hospitalized patients with ACS included in the study, only 19.4% continued DAPT to 12 months. On the other hand, the East Asian ACS patient population has a higher risk of bleeding than the Western patient population, and gastrointestinal bleeding is the most common type of bleeding in ACS patients after percutaneous coronary intervention. Therefore, there is a need for more practical and effective means to help solve the dilemma of antiplatelet therapy.
It is reported that the clopidogrel-aspirin tablet listed this time is a single-tablet compound preparation (SPC). It is released, does not dissolve in the stomach, and has a rapid onset of action, thereby reducing gastrointestinal adverse reactions caused by aspirin. At the same time, the daily administration of one tablet not only reduces the patient’s medication burden, but also improves the patient’s medication compliance and further improves the patient’s clinical prognosis.
Image source: provided by respondents